Neurophysiological and Neurochemical Effects of the Putative Cognitive Enhancer (

Action Potentials Animals Benzhydryl Compounds / pharmacology Cognition Dopamine / metabolism Dopamine Agents / pharmacology Dopamine Plasma Membrane Transport Proteins / antagonists & inhibitors Dopaminergic Neurons / drug effects Limbic System / drug effects Male Nootropic Agents / pharmacology Prefrontal Cortex / cytology Pyramidal Cells / drug effects Rats Rats, Sprague-Dawley Reward
cognitive enhancer dopamine dopamine transporter modafinil prefrontal cortex psychostimulants reward

Journal

Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414

Informations de publication

Date de publication:
18 05 2020
Historique:
received: 02 04 2020
revised: 14 05 2020
accepted: 15 05 2020
entrez: 24 5 2020
pubmed: 24 5 2020
medline: 7 4 2021
Statut: epublish

Résumé

Treatments for cognitive impairments associated with neuropsychiatric disorders, such as attention deficit hyperactivity disorder or narcolepsy, aim at modulating extracellular dopamine levels in the brain. CE-123 (5-((benzhydrylsulfinyl)methyl) thiazole) is a novel modafinil analog with improved specificity and efficacy for dopamine transporter inhibition that improves cognitive and motivational processes in experimental animals. We studied the neuropharmacological and behavioral effects of the

Identifiants

DOI: 10.3390/biom10050779 PMID: 32443397 PMC: PMC7277835
pubmed: 32443397
pii: biom10050779
doi: 10.3390/biom10050779
pmc: PMC7277835
pii:
doi:

Substances chimiques

Benzhydryl Compounds 0
CE-123 0
Dopamine Agents 0
Dopamine Plasma Membrane Transport Proteins 0
Nootropic Agents 0
Dopamine VTD58H1Z2X

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Regione Autonoma della Sardegna
ID : RASSR50209
Pays : International
Organisme : Università degli Studi di Cagliari
ID : PRID 2017
Pays : International

Références

J Clin Psychopharmacol. 2016 Feb;36(1):98-100
pubmed: 26658262
Neuropsychiatr Dis Treat. 2007 Jun;3(3):349-64
pubmed: 19300566
Curr Top Behav Neurosci. 2016;27:231-57
pubmed: 26323245
Mol Neurobiol. 2019 May;56(5):3563-3575
pubmed: 30151725
J Affect Disord. 2016 Jun;197:51-7
pubmed: 26970266
Neuroreport. 2001 Nov 16;12(16):3533-7
pubmed: 11733706
Drug Alcohol Depend. 2010 Jun 1;109(1-3):20-9
pubmed: 20092966
Neuroscience. 1998 Dec;87(4):905-11
pubmed: 9759978
Nat Neurosci. 2007 Mar;10(3):376-84
pubmed: 17277774
Neuroscience. 2014 Dec 12;282:217-29
pubmed: 25241063
Front Neurosci. 2013 Nov 05;7:201
pubmed: 24204329
Psychiatry Investig. 2018 Apr;15(4):424-427
pubmed: 29593204
Curr Neuropharmacol. 2015;13(2):164-79
pubmed: 26411760
J Clin Psychopharmacol. 2004 Feb;24(1):87-90
pubmed: 14709953
J Pharmacol Exp Ther. 2006 Nov;319(2):561-9
pubmed: 16885432
Neurosci Biobehav Rev. 1998 Mar;22(2):347-54
pubmed: 9579324
J Pharmacol Exp Ther. 2010 Feb;332(2):463-8
pubmed: 19843976
Neuropharmacology. 2014 Aug;83:128-36
pubmed: 24769001
J Affect Disord. 2015 Aug 1;181:87-91
pubmed: 25933099
Trends Cogn Sci. 2019 Mar;23(3):213-234
pubmed: 30711326
Biol Psychiatry. 2006 Nov 15;60(10):1111-20
pubmed: 16806100
Am J Psychiatry. 2006 Jul;163(7):1282-4
pubmed: 16816237
Drug Alcohol Depend. 2009 Sep 1;104(1-2):133-9
pubmed: 19560290
Front Behav Neurosci. 2017 Nov 27;11:222
pubmed: 29230168
Int J Eat Disord. 2013 Jul;46(5):492-5
pubmed: 23658098
Neuropsychopharmacology. 2016 Sep;41(10):2424-46
pubmed: 26934955
Behav Brain Res. 2018 May 2;343:83-94
pubmed: 29410048
Front Pharmacol. 2019 Jun 28;10:682
pubmed: 31316379
J Neurosci. 1984 Nov;4(11):2866-76
pubmed: 6150070
Front Public Health. 2017 Sep 26;5:260
pubmed: 29034227
Behav Brain Res. 2009 Jan 30;197(1):205-9
pubmed: 18809437
Neuropharmacology. 2012 Aug;63(2):224-34
pubmed: 22465816
Psychopharmacology (Berl). 2015 Apr;232(8):1427-40
pubmed: 25345736
Pharmacol Rev. 2011 Mar;63(1):182-217
pubmed: 21303898
PLoS One. 2017 Jun 23;12(6):e0179675
pubmed: 28644892
Proc Natl Acad Sci U S A. 1988 Jul;85(14):5274-8
pubmed: 2899326
Front Behav Neurosci. 2019 Apr 11;13:63
pubmed: 31031603
J Neurosci. 1984 Nov;4(11):2877-90
pubmed: 6150071
Int J Neuropsychopharmacol. 2014 Mar;17(3):429-41
pubmed: 24138707
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jan 1;32(1):145-9
pubmed: 17765380
Biol Psychiatry. 2013 Apr 15;73(8):789-95
pubmed: 23399373
Drug Alcohol Depend. 2012 Jan 1;120(1-3):135-41
pubmed: 21840138
Neurosci Lett. 1991 Feb 11;123(1):20-2
pubmed: 1676498
Behav Brain Res. 2006 Mar 15;168(1):64-73
pubmed: 16343652
Int J Eat Disord. 2014 Jan;47(1):24-31
pubmed: 24166941
Nature. 1997 Apr 24;386(6627):827-30
pubmed: 9126740
Biol Psychiatry. 2004 Jul 15;56(2):86-94
pubmed: 15231440
J Neurosci. 1988 Jan;8(1):100-12
pubmed: 3339402
Neuropharmacology. 2013 Jan;64:168-84
pubmed: 22820555
Biochem Pharmacol. 2008 Jan 1;75(1):196-217
pubmed: 17825265
Neuropharmacology. 2004;47 Suppl 1:227-41
pubmed: 15464140
Front Behav Neurosci. 2019 Mar 01;13:24
pubmed: 30881293
Curr Psychiatry Rep. 2017 Jan;19(1):7
pubmed: 28144880
Front Neuroanat. 2017 Sep 28;11:87
pubmed: 29033796
ACS Chem Neurosci. 2019 Apr 17;10(4):2012-2021
pubmed: 30645944
Addict Biol. 2014 Jan;19(1):49-60
pubmed: 23017017
PLoS One. 2012;7(1):e28331
pubmed: 22253689
NIDA Res Monogr. 1989;95:239-46
pubmed: 2561828
Science. 2008 Dec 12;322(5908):1700-2
pubmed: 19074351
Metab Brain Dis. 2018 Jun;33(3):893-906
pubmed: 29470766
Front Behav Neurosci. 2015 Aug 19;9:215
pubmed: 26347626
Behav Neurosci. 2001 Aug;115(4):940-4
pubmed: 11508733
Eur Neuropsychopharmacol. 2015 Mar;25(3):343-55
pubmed: 25638025
Psychopharmacology (Berl). 2011 Aug;216(3):345-53
pubmed: 21340470
Pharmacol Res. 2016 Jul;109:108-18
pubmed: 26826399
Eur J Neurosci. 2017 Jan;45(1):167-174
pubmed: 27545285
JAMA. 2009 Mar 18;301(11):1148-54
pubmed: 19293415
Curr Opin Neurol. 2003 Dec;16 Suppl 2:S3-9
pubmed: 15129844
Neuropharmacology. 2013 Jan;64:321-8
pubmed: 22796428
Eur J Neurosci. 2017 Jan;45(1):20-33
pubmed: 27520881
Psychopharmacology (Berl). 2013 Oct;229(3):415-34
pubmed: 23934211
J Am Acad Child Adolesc Psychiatry. 2007 Mar;46(3):341-355
pubmed: 17314720
Neuropsychopharmacology. 2012 Feb;37(3):822-37
pubmed: 22048464
Biol Psychiatry. 2012 Sep 1;72(5):405-13
pubmed: 22537794
J Neurosci Methods. 2018 Dec 1;310:33-44
pubmed: 29959002

Auteurs

Claudia Sagheddu (C)

Department of Biomedical Sciences, Division of Neuroscience and Clinical Pharmacology, University of Cagliari, 09042 Monserrato, Italy.
ORCID: 0000-0002-5315-2898

Nicholas Pintori (N)

Department of Biomedical Sciences, Division of Neuroscience and Clinical Pharmacology, University of Cagliari, 09042 Monserrato, Italy.

Predrag Kalaba (P)

Department of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna, 1010 Vienna, Austria.

Vladimir Dragačević (V)

Department of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna, 1010 Vienna, Austria.

Gessica Piras (G)

Department of Biomedical Sciences, Division of Neuroscience and Clinical Pharmacology, University of Cagliari, 09042 Monserrato, Italy.

Jana Lubec (J)

Department of Neuroproteomics, Paracelsus Medical University, 5020 Salzburg, Austria.

Nicola Simola (N)

Department of Biomedical Sciences, Division of Neuroscience and Clinical Pharmacology, University of Cagliari, 09042 Monserrato, Italy.

Maria Antonietta De Luca (MA)

Department of Biomedical Sciences, Division of Neuroscience and Clinical Pharmacology, University of Cagliari, 09042 Monserrato, Italy.
ORCID: 0000-0002-2647-4859

Gert Lubec (G)

Department of Neuroproteomics, Paracelsus Medical University, 5020 Salzburg, Austria.

Marco Pistis (M)

Department of Biomedical Sciences, Division of Neuroscience and Clinical Pharmacology, University of Cagliari, 09042 Monserrato, Italy.
Neuroscience Institute, National Research Council of Italy (CNR), Section of Cagliari, 09100 Cagliari, Italy.
ORCID: 0000-0002-4622-3205

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Meal Timing and Anthropometric and Metabolic Outcomes: A Systematic Review and Meta-Analysis.

Hiu Yee Liu, Ashley A Eso, Nathan Cook et al.
1.00
Humans Meals Time Factors Female Adult

Classifications MeSH

questionsmedicales.fr › Phénomènes physiologiques de l'appareil locomoteur et du système nerveux › Phénomènes physiologiques du système nerveux › Potentiels de membrane › Potentiels d'action › Neurophysiological and Neurochemical Effects...
questionsmedicales.fr › Eucaryotes › Animaux › Neurophysiological and Neurochemical Effects...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Hydrocarbures cycliques › Hydrocarbures aromatiques › Dérivés du benzène › Composés benzhydryliques › Neurophysiological and Neurochemical Effects...
questionsmedicales.fr › Phénomènes psychologiques › Processus mentaux › Cognition › Neurophysiological and Neurochemical Effects...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Hydrocarbures cycliques › Hydrocarbures aromatiques › Dérivés du benzène › Phénols › Catéchols › Catécholamines › Dopamine › Neurophysiological and Neurochemical Effects...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents neuromédiateurs › Agents dopaminergiques › Neurophysiological and Neurochemical Effects...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Protéines de transport membranaire › Protéines transporteurs de solutés › Transporteurs de la dopamine › Neurophysiological and Neurochemical Effects...
questionsmedicales.fr › Cellules › Neurones › Neurones dopaminergiques › Neurophysiological and Neurochemical Effects...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Système limbique › Neurophysiological and Neurochemical Effects...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents du système nerveux central › Nootropiques › Neurophysiological and Neurochemical Effects...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Prosencéphale › Télencéphale › Cerveau › Cortex cérébral › Lobe frontal › Cortex préfrontal › Neurophysiological and Neurochemical Effects...
questionsmedicales.fr › Cellules › Neurones › Cellules pyramidales › Neurophysiological and Neurochemical Effects...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Rats › Neurophysiological and Neurochemical Effects...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Rats › Rat Sprague-Dawley › Neurophysiological and Neurochemical Effects...
questionsmedicales.fr › Phénomènes psychologiques › Processus mentaux › Renforcement (psychologie) › Récompense › Neurophysiological and Neurochemical Effects...